The overarching aim of our group is to discover ways to further personalize cancer treatment in order to improve individual patient outcomes. Our first specific aim is focused on understanding how conditions of low oxygen (hypoxia) influence the biology of tumour cells in ways that are critical for tumour cell behaviour and response to treatment. Within this area, 4 different adaptive responses to hypoxia are being investigated. We discovered new details about how each of these pathways influences the biology of hypoxic cancer cells, and we are now testing new therapeutic approaches that exploit this understanding. We also have developed novel methods for measuring hypoxia and the microenvironment of tumours that have promising research and clinical applications. The second major area of investigation utilizes novel technologies that can globally assess the importance of all genes in parallel. This technology is part of several studies to identify new therapeutic targets in head and neck cancer, colon, prostate, and cervix cancer. Recent studies have continued to identify potential targets in each of these disease areas that could be useful either on their own or in combination with radiotherapy or chemotherapy.
Bradly G Wouters, BEng, PhD
Senior Scientist, Princess Margaret Cancer Centre
Executive VP Science and Research, University Health Network